Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
      QxMD      Google Scholar   
Citation:
Blood Cancer J vol 12 (4)
Year:
2022
Type:
Manuscript
Funding:
AFT
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub-ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
11
Parents:
3411   3827  
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Janssen Oncology  
Grants:
 
Corr. Author:
 
Authors:
                                         
Networks:
KANSAS, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, MD015, NC002, NE003, OH008   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: